Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Renal Cancer Clinical Trials

A listing of Renal Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (8) clinical trials

Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma

This is a Phase II, open-label, safety, pharmacodynamic and efficacy study of entinostat in combination with nivolumab and ipilimumab in subjects with metastatic renal cell carcinoma (RCC) who have progressed on ipilimumab + nivolumab regimen. Prior to Phase II, a safety lead-in will be conducted to establish the RP2D of ...

Phase

Renal Adjuvant MultiPle Arm Randomised Trial

RATIONALE: The current global standard of care after nephrectomy for localised RCC therefore remains active monitoring (i.e., observation by clinical and radiological means). 30-40% patients with initially localised RCC develop metastatic disease following nephrectomy. Need for adjuvant therapy is most marked in the high risk population where outcomes are predictably ...

Phase

TFE Renal Cell Carcinoma: A Prospective Registry and Translational Research Initiative

The following data/materials will be collected for this registry study: Clinical Data: Demographic data, date of diagnosis, pathology, radiological imaging at diagnosis and relapse, signs and symptoms at diagnosis, molecular and biological data, staging details including sites of disease, detailed treatment data (e.g. types and dates of surgeries/interventional therapy (if ...

Phase N/A

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with select advanced malignancies.

Phase

CBT-501 or Nivolumab in Combination With CBT-101 in Locally Advanced or Metastatic HCC and RCC

For each potential subject, there is a 28-day screening and eligibility assessment period before enrollment; the first dose of study treatment will be administered on Day 1 of Cycle 1 (C1D1) (Safety population). Subjects will continue to receive their assigned treatment throughout the study until the occurrence of confirmed disease ...

Phase

First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b

This is a multi-center study of XMT-1536 in patients with tumors likely to express NaPi2b, focusing on patients with platinum-resistant ovarian cancer and non-squamous non-small cell lung cancer. XMT-1536 will be administered as an intravenous infusion once every three weeks. The study consists of two segments: dose escalation (DES) and ...

Phase

Zero-ischemia Robot-assisted Partial Nephrectomy Using Near-infrared Fluorescence

Patients with renal cancer are commonly treated by robot-assisted partial nephrectomy. Renal artery clamping is commonly required inducing kidney ischemia during surgery. It impacts parenchymal and renal function. This study aims to compare a new surgical procedure in order to reduce ischemia effect and preserve renal function after partial nephrectomy ...

Phase N/A

Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases

This is a multicenter, randomized, double blind, Phase II study. Participants eligible for this study have metastatic urothelial cancer and bone metastases and are planned to receive 4-6 cycles of a standard of care platinum-doublet regimen. In a double blind manner, 50 participants will be randomized in a 1:1 ratio ...

Phase